Marshall Wace’s Collegium Pharmaceutical COLL Stock Holding History

Marshall Wace’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.17M	Sell	253,353 -495,459	-66%	-$16.9M	0.01%	1076
2026 Q1	$24.8M	Buy	748,812 +256,452	+52%	+$10.9M	0.02%	621
2025 Q4	$22.8M	Buy	492,360 +213,347	+76%	+$8.93M	0.02%	591
2025 Q3	$9.76M	Buy	279,013 +142,292	+104%	+$4.95M	0.01%	925
2025 Q2	$4.04M	Buy	+136,721	New	+$3.9M	﹤0.01%	1250
2024 Q3	–	Sell	-70,964	Closed	-$2.29M	–	2564
2024 Q2	$2.29M	Buy	+70,964	New	+$2.46M	﹤0.01%	1304
2024 Q1	–	Sell	-136,049	Closed	-$4.19M	–	2492
2023 Q4	$4.19M	Sell	136,049 -250,247	-65%	-$6.27M	0.01%	969
2023 Q3	$8.63M	Sell	386,296 -108,180	-22%	-$2.47M	0.02%	693
2023 Q2	$10.6M	Sell	494,476 -85,435	-15%	-$1.94M	0.02%	708
2023 Q1	$13.9M	Buy	579,911 +272,881	+89%	+$7.24M	0.03%	595
2022 Q4	$7.12M	Buy	307,030 +267,065	+668%	+$5.39M	0.02%	993
2022 Q3	$640K	Buy	+39,965	New	+$705K	﹤0.01%	2621
2021 Q3	–	Sell	-11,718	Closed	-$277K	–	3069
2021 Q2	$277K	Buy	+11,718	New	+$271K	﹤0.01%	2350
2019 Q2	–	Sell	-56,961	Closed	-$862K	–	1422
2019 Q1	$862K	Buy	+56,961	New	+$912K	0.01%	981

Other funds holding COLL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Marshall Wace's COLL Position: Q2 2026 in Review

Marshall Wace reduced its Collegium Pharmaceutical (COLL) stake by 66% in Q2 2026, selling an estimated $16.9M and leaving 253,353 shares worth $9.17M. The position accounts for 0.01% of the portfolio, ranked #1076.

Marshall Wace first reported a position in COLL in Q1 2019 and has held it in 14 quarters since. The position peaked at $24.8M in Q1 2026. 280 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

Marshall Wace held 253,353 shares of Collegium Pharmaceutical worth $9.17M as of Q2 2026.
Marshall Wace sold 495,459 Collegium Pharmaceutical shares in Q2 2026, an estimated $16.9M.
Collegium Pharmaceutical made up 0.01% of Marshall Wace's portfolio in Q2 2026, its #1076 holding.
Marshall Wace first reported a position in Collegium Pharmaceutical in Q1 2019 and has held it in 14 quarters since.
Marshall Wace's Collegium Pharmaceutical position peaked at $24.8M in Q1 2026.
280 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.